GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acumen Pharmaceuticals Inc (NAS:ABOS) » Definitions » 3-Year FCF Growth Rate

Acumen Pharmaceuticals (Acumen Pharmaceuticals) 3-Year FCF Growth Rate : -50.50% (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Acumen Pharmaceuticals 3-Year FCF Growth Rate?

Acumen Pharmaceuticals's Free Cash Flow per Share for the three months ended in Dec. 2023 was $-0.14.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was -50.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 5 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Acumen Pharmaceuticals was -50.50% per year. The lowest was -54.00% per year. And the median was -52.25% per year.


Competitive Comparison of Acumen Pharmaceuticals's 3-Year FCF Growth Rate

For the Biotechnology subindustry, Acumen Pharmaceuticals's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Acumen Pharmaceuticals's 3-Year FCF Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Acumen Pharmaceuticals's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where Acumen Pharmaceuticals's 3-Year FCF Growth Rate falls into.



Acumen Pharmaceuticals 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.


Acumen Pharmaceuticals  (NAS:ABOS) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.


Acumen Pharmaceuticals 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of Acumen Pharmaceuticals's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Acumen Pharmaceuticals (Acumen Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
427 Park Street, Charlottesville, VA, USA, 22902
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believe to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody which selectively targets amyloid-beta oligomers.
Executives
Daniel Joseph Oconnell director, officer: President and CEO C/O ACUMEN PHARMACEUTICALS, INC., 427 PARK STREET, CHARLOTTESVILLE VA 22902
Derek M Meisner officer: Chief Legal Office & Corp Sec C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140
Eric Siemers officer: Chief Medical Officer C/O ACUMEN PHARMACEUTICALS, INC., 427 PARK STREET, CHARLOTTESVILLE VA 22902
Russell Barton officer: Chief Operating Officer C/O ACUMEN PHARMACEUTICALS, INC., 427 PARK STREET, CHARLOTTESVILLE VA 22902
Matt Zuga officer: Chief Financial Officer C/O TELA BIO, INC., 1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN PA 19355
Jeffrey L. Ives director C/O CARA THERAPEUTICS, INC., 1 PARROTT DRIVE, SHELTON CT 06484
Ra Capital Healthcare Fund Lp director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Derrell Porter director C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BLVD. #900, SOUTH SAN FRANCISCO CA 94080
Kimberlee C Drapkin director PREDIX PHARMACEUTICALS HOLDINGS, INC., 4 MAGUIRE ROAD, LEXINGTON MA 02421
Paul B Manning 10 percent owner 200 GARRETT STREET SUITE S, CHARLOTTESVILLE VA 22902
Stalfort John A Iii director C/O ACUMEN PHARMACEUTICALS, INC., 427 PARK STREET, CHARLOTTESVILLE VA 22902
Robert D. Hardie 10 percent owner 210 RIDGE MCINTIRE ROAD, SUITE 350, CHARLOTTESVILLE VA 22903
Nathan B Fountain director C/O ACUMEN PHARMACEUTICALS, INC., 427 PARK STREET, CHARLOTTESVILLE VA 22902
Sands Capital Global Venture Fund Ii, L.p. 10 percent owner C/O SANDS CAPITAL VENTURES, LLC, 1000 WILSON BOULEVARD, SUITE 3000, ARLINGTON VA 22209
Sands Capital Life Sciences Pulse Fund, Llc 10 percent owner C/O SANDS CAPITAL VENTURES, LLC, 1000 WILSON BOULEVARD, SUITE 3000, ARLINGTON VA 22209